MediciNova enters new executive employment agreements with CEO and Chief Medical Officer
On August 17, 2026, MediciNova signed new executive employment agreements with CEO Yuichi Iwaki and Chief Medical Officer Kazuko Matsuda, replacing their prior employment and severance arrangements. The agreements set base salaries, bonus targets and enhanced change-in-control severance, which matters to shareholders because it defines potential future costs tied to these executives.
Key points
- Dr. Iwaki's base salary is $690,246 with a target bonus of 55% of salary; Dr. Matsuda's base salary is $540,143 with a target bonus of 40%.
- Following a change in control, Dr. Iwaki would receive 24 months of base salary plus 24 months of target bonus; Dr. Matsuda would receive 18 months of each.
- Without a change in control, involuntary termination pays 12 months of base salary for both executives.
- The full agreements will be filed with the Form 10-Q for the quarter ended September 30, 2026.
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 19, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.